Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/41929
Título: Plasma trimethylamine-N-oxide and related metabolites are associated to type 2 diabetes risk in the PREDIMED trial (P 146-T)
Autores/as: Papandreou, C.
Bullo, M.
Zheng, Y.
Ruíz-Canela, M.
Yu, E.
Guasch-Ferre, M.
Toledo, E.
Clish, C.
Corella, D.
Estruch, R.
Ros, E.
Fito, M.
Aros, F.
Fiol, M.
Lapetra, J.
Serra-Majem, Ll 
Gómez-Gracía, E.
Liang, L.
Fragkiadakis, G.
Razquin, C.
Hu, F.
Salas-Salvado, J.
Clasificación UNESCO: 3206 Ciencias de la nutrición
Fecha de publicación: 2018
Publicación seriada: European journal of clinical investigation (Print) 
Conferencia: 52nd Annual Scientific Meeting of the European Society for Clinical Investigation “Precision medicine for healthy ageing”, Barcelona, Spain, 30th May – 1st June 2018
Resumen: Background: The role of trimethylamine-N-oxide (TMAO) in type 2 diabetes (T2D) is currently partially understood and controversial. We aimed to investigate associations between TMAO and related metabolites with type 2 diabetes (T2D) risk in subjects at high risk of cardiovascular disease. Material and methods: This is a case-cohort design study within the PREDIMED study, with 251 incident T2D cases and a random sample of 694 participants (641 non-cases and 53 overlapping cases) without T2D at baseline (median follow-up: 3·8 years). We used liquid chromatography-tandem mass spectrometry to measure plasma TMAO, L-carnitine, betaine, lyso-phosphatidylcholine (LPC) and lyso-phosphatidylethanolamine (LPE) species, phosphocholine, alpha-glycerophosphocholine, choline, at baseline and 1-year. We examined associations using weighted Cox proportional hazard models; accounting for the weighted case-cohort design by the Barlow method. Results: After adjusting for recognized T2D risk factors and multiple testing, individuals in the highest quartile of baseline TMAO and alpha-glycerophosphocholine had lower risk of T2D; hazard ratio (HR) 0·52 (95% CI 0·29, 0·89), and 0·46 (95% CI 0·24, 0·89), respectively. The HR (95% CI) comparing the extreme quartiles of betaine was 0·41 (0·23, 0·74). Similar trends were observed for C16:0 LPC, C18:1 LPC, C18:0 LPC, C20:4 LPC, C22:6 LPC, C18:1 LPC plasmalogen and C16:0 LPE. After correcting for multiple comparisons, participants in the highest quartile of 1-year changes in C18:1 LPC plasmalogen levels had lower T2D risk as compared to the reference quartile. Conclusions: Whether the associations between plasma TMAO and certain metabolites levels with T2D risk reflect its pathophysiology or represent an epiphenomenon need to be elucidated.
URI: http://hdl.handle.net/10553/41929
ISSN: 0014-2972
DOI: 10.1111/eci.12926
Fuente: European Journal of Clinical Investigation [ISSN 0014-2972], v. 48 (S1), p. 176-176
Colección:Póster de congreso
miniatura
pdf
Adobe PDF (45,83 kB)
Vista completa

Visitas

99
actualizado el 18-may-2024

Descargas

93
actualizado el 18-may-2024

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.